 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dr. Reddy’s Laboratories Share Price | Nerivio is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe.

Dr Reddy’s dips despite launching migraine management device in Europe

After its launch in the European market, Nerivio will be introduced in South Africa later in April, followed by Spain and the UK

Dr Reddy's launches drug-free migraine management device in Germany

After witnessing consistent double-digit growth in branded formulations business in recent years, growth in the domestic formulation segment has moderated to high single digits

Steady US sales to bring a healthy quarter for pharma sector

Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6537 in its research report dated April 01, 2024.

Buy Dr Reddy’s Laboratories; target of Rs 6537: Sharekhan

Dr Reddy’s Laboratories | A meeting of the board of directors of the company will be held on Tuesday, May 7, 2024, to consider and approve the audited standalone and consolidated financial results of the company.

Dr Reddy’s gains on distribution tie-up with Sanofi Healthcare

Under the arrangement, Dr Reddy’s will have exclusive rights to promote and distribute Sanofi's paediatric and adult vaccine brands. Shares of Dr Reddy's Laboratories Ltd ended at ₹6,052.50, down by ₹74.45, or 1.22%, on the BSE.

Dr Reddy's partners with Sanofi for distribution of vaccine brands in India

The first-in-class innovative drug, centhaquine, is a resuscitative agent presently indicated for the treatment of hypovolemic shock. Shares of Dr Reddy's Laboratories Ltd ended at ₹6,197.50, up by ₹68.30, or 1.11%, on the BSE.

Dr Reddy's partners with US-based Pharmazz to launch innovative critical care drug in India

Dr Reddy's partners with US-based Pharmazz to launch new critical care drug centhaquine in India

CNBC-TV18 had earlier reported that the Hyderabad-based Dr Reddy's Laboratories may buy the Novartis unit on sale. The partnership with DRL already accounts for 50% of Novartis' drug sales in India. Watch how Vas Narasimhan, Novartis' global CEO, responded. 

EXCLUSIVE | Novartis global CEO says he wants a better owner for its listed entity in India

EXCLUSIVE | Novartis CEO says he wants a better owner for its listed entity in India

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Volume (M)	342,651.00
52-Wk High	6,600.00
52-Wk Low	4,384.05

Current Price	5,940.00
Prev Close	5,976.40
Open	6,000.00
Dividend Yield	0.87%
50-Day Moving Average	6,249.78
Beta	0.00
Avg. Volume	257,712.61
PE Ratio	18.94

52-Week High	6,600.00
52-Week Low	4,384.05
Market Capitalization	989.57B
EPS	313.75
Price to Book	3.69
Revenue Per Employee	10.49M
Enterprise Value/EBITDA	12.20

DRREDDY.NSE Dr. Reddy`s Laboratories Ltd.

About

Feed

News

Sentiment

Fundamentals